Forma Therapeutics Holdings Inc

NASDAQ:FMTX   3:59:55 PM EDT
17.56
-0.08 (-0.45%)
Products

Forma Therapeutics Holdings Inc FT-7051 Yields Positive Initial Results From Ongoing Phase 1 Courage Study

Published: 10/07/2021 11:17 GMT
Forma Therapeutics Holdings Inc (FMTX) - Forma Therapeutics’ Ft-7051 is Well-tolerated and Demonstrates Evidence of Activity in Initial Results From Ongoing Phase 1 Courage Study in Men With Metastatic Castration-resistant Prostate Cancer.
Forma Therapeutics Holdings Inc - Adaptive Trial Design Intended to Efficiently Explore Safe and Efficacious Doses of Ft-7051.
Forma Therapeutics Holdings Inc - First Evaluable Patient Completing More Than 90 Days of Treatment Demonstrated an Ongoing Psa50 Response.
Forma Therapeutics Holdings Inc - Pharmacodynamic Evidence of Activity Demonstrated Via Skin Biomarker; No Discontinuations Due to Adverse Events.